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 Despite signifi cant advances in its treatment, coronary 
artery disease (CAD) remains the leading cause of morbid-
ity and mortality worldwide ( 1 ). Consequently, new thera-
peutic strategies are needed to further improve outcomes. 
The discovery of biomarkers involved in the pathogenesis 
of CAD offers considerable promise to facilitate the devel-
opment of novel therapeutics and identify subsets of high-
risk patients who may derive the greatest benefi t from 
therapy ( 2 ). 
 In addition to their role as xenobiotic metabolizing en-
zymes, cytochromes P450 (CYPs) metabolize fatty acids to 
bioactive lipids that regulate numerous cellular and physi-
ological processes relevant to the pathogenesis of CAD 
( 3 ). Most notably, CYP epoxygenases from the CYP2C and 
CYP2J subfamilies metabolize arachidonic acid (AA) into 
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revascularization procedure (if indicated). Plasma was immedi-
ately separated by centrifugation and stored at   80°C. 
 Classifi cation of CAD extent 
 The extent of CAD was classifi ed based on the results of the 
coronary angiography. Obstructive CAD was defi ned according 
to the anatomical or physiological “criteria for revascularization” 
from recent clinical practice guidelines ( 12 ). Briefl y, the ana-
tomic criteria for revascularization [percutaneous coronary in-
tervention (PCI) or coronary artery bypass grafts (CABGs)] are 
the presence of   50% stenosis in the left main coronary artery or 
  70% stenosis in one or more of the nonleft main coronary ar-
teries. The classifi cation of nonobstructive CAD included those 
without obstructive CAD that had mild stenosis (10–69% in one 
or more nonleft main coronary arteries and/or 10–49% stenosis 
in the left main coronary artery), whereas the classifi cation of no 
apparent CAD included those with no angiographic evidence of 
CAD (<10% stenosis in all coronary arteries). Only unprotected 
lesions (lesions not bypassed by collateral vessels, bypass grafts, or 
stents) in native coronary arteries were considered for classifi ca-
tion in order to refl ect the current extent of coronary artery ste-
nosis at the time of blood sampling that was unrelated to a prior 
revascularization procedure. 
 Quantifi cation of eicosanoid metabolite concentrations 
 Free plasma eicosanoid metabolite concentrations were quan-
tifi ed using an LC/MS/MS method with optimized sensitivity 
and specifi city for EET quantifi cation, as previously described 
with minor modifi cations ( 13, 14 ). Briefl y, plasma (0.25 ml) was 
diluted in 0.1% acetic acid/5% methanol solution (0.25 ml) con-
taining 0.009 mM butylated hydroxytoluene (BHT), spiked with 
internal standards [3 ng each of prostaglandin E 2 -d4 (Cayman 
Chemical, Ann Arbor, MI), 10,11-dihydroxynondecanoic acid, 
and 10,11-epoxyheptadecanoid acid (kindly provided by Dr. 
Bruce Hammock, University of California, Davis; Ref.  15 )], and 
processed by liquid-liquid extraction (0.1% acetic acid/5% meth-
anol and ethyl acetate) to isolate lipids. Extracts in ethyl acetate 
were then dried by centrifugation under vacuum, covered in ar-
gon, and stored at   80°C for future processing. Dried extracts 
were reconstituted in 80% methanol (containing 10 mg/ml BHT) 
for elution through phospholipid removal columns (Phree; Phe-
nomenex, Torrance, CA), as directed by the manufacturer. Phos-
pholipid removal enhances purifi cation of the extracts, thereby 
reducing matrix ion suppression and improving signal-to-noise 
ratio ( 16 ). Phospholipid-free extracts were then dried a second 
time by centrifugation under vacuum and stored at   80°C. At 
the time of analysis, extracts were reconstituted in 50   l of 30% 
ethanol, and a panel of 34 eicosanoid metabolites (supplemen-
tary Table 1) was quantifi ed by targeted LC/MS/MS, as previ-
ously described ( 13, 14 ). 
 Concentration values falling below the lower limit of quantita-
tion were imputed as a concentration equal to half of the lowest 
standard. Analytes with >50% of the values below or above the 
lower or upper limit of quantitation, respectively, were not in-
cluded in the analysis (supplementary Table 1) ( 13 ). Among the 
28 metabolites that met these criteria, 24 of 28 (86%) had <10% 
values out of the quantitation range. Free plasma concentrations 
ranged from nanomolar to micromolar. 
 Gene expression in peripheral blood mononuclear cells 
 Peripheral blood mononuclear cells (PBMCs) were isolated in 
98 participants enrolled between July 2013 and February 2014. 
Briefl y, blood (5 ml) was centrifuged over a density gradient me-
dium (Lymphoprep; Axis Shield, Oslo, Norway). Cells were col-
lected at the interface, washed with cold PBS, and homogenized. 
four epoxyeicosatrienoic acid (EET) regioisomers (5,6-, 
8,9-, 11,12-, and 14,15-EET) with varying regioselectivity 
( 4 ). The EETs elicit potent vasodilatory, anti-infl ammatory, 
and cellular protective effects in the cardiovascular sys-
tem but are rapidly hydrolyzed by soluble epoxide hy-
drolase (sEH;  EPHX2 ) into dihydroxyeicosatrienoic acids 
(DHETs) ( 5, 6 ). 
 Promoting the effects of EETs yields potent cardiovascu-
lar protective effects in preclinical models of vascular 
infl ammation, atherosclerosis, and myocardial ischemia-
reperfusion injury ( 5–7 ). In epidemiological studies, asso-
ciations between functional polymorphisms in genes 
responsible for EET biosynthesis ( CYP2C8, CYP2J2 ) or 
EET hydrolysis ( EPHX2 ) and the development of CAD 
have been reported ( 8–10 ). Taken together, these data 
suggest that increasing CYP-derived EET levels may be a 
viable therapeutic strategy for CAD. However, because 
EETs are not measured on traditional metabolomic or 
eicosanoid analytical platforms ( 11 ), major gaps in knowl-
edge surrounding the biological and therapeutic impor-
tance of EETs in human CAD exist. Quantifying EET 
metabolite levels offers the potential to identify key factors 
that impact EET biosynthesis and EET hydrolysis, beyond 
germ-line genetic polymorphisms, and facilitate the ratio-
nal design of clinical trials with emerging therapies that 
target the EET metabolic pathway. 
 The primary objective of the current study was 2-fold:  1 ) 
to elucidate the relationship between CYP-derived EET 
levels and the angiographic extent of CAD and  2 ) to evalu-
ate the strength of this association relative to eicosanoids 
derived from the CYP hydroxylase, cyclooxygenase (COX), 
and lipoxygenase (LOX) metabolic pathways. In order to 
accomplish these objectives, a panel of 28 CYP-, COX-, and 
LOX-derived lipid metabolites was quantifi ed in a cohort 
of patients referred for coronary angiography with sus-
pected or worsening obstructive CAD using a targeted me-
tabolomics approach. 
 MATERIALS AND METHODS 
 Study population 
 A cohort of individuals 18–80 years of age referred for coro-
nary angiography to detect new or worsening CAD were identi-
fi ed in the cardiac catheterization laboratories at the University 
of North Carolina at Chapel Hill (UNC) between September 
2012 and February 2014. Exclusion criteria included severe con-
current illness (such as active pneumonia or acute decompensated 
heart failure), systemic infl ammatory disease (such as rheuma-
toid arthritis), cancer actively being treated, hematologic disor-
ders affecting platelet function, prior heart transplantation, 
hematocrit <30%, ST segment elevation myocardial infarction 
(STEMI), end-stage liver disease, end-stage renal disease on dial-
ysis, and systemic immunosuppressive medication use (such as 
corticosteroid use). Eligible participants provided written in-
formed consent. The study protocol was approved by the UNC 
Biomedical Institutional Review Board. 
 Whole blood was drawn in the catheterization lab from the 
indwelling arterial sheath after it had been placed as part of 
the coronary angiography procedure, but before initiation of a 
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factors, multiple regression analysis was also performed. Potential 
covariates included demographic factors (age, gender, African 
American race), cardiovascular risk factors (obesity, hyperten-
sion, diabetes, cigarette smoking, hyperlipidemia, peripheral ar-
tery disease, prior acute myocardial infarction, prior stroke), 
comorbidities (lung disease, heart failure), body mass index, and 
chronic medication use preangiography (angiotensin-converting 
enzyme inhibitor, angiotensin receptor blockers, aspirin, beta 
blockers, statins, calcium channel blockers, P2Y 12 inhibitors, met-
formin, nitrates, nonstatin lipid modifi ers, fi sh oil, proton pump 
inhibitors), and indices of CAD extent (current ACS, presence of 
collaterals, maximum coronary artery stenosis, postangiography 
revascularization procedure). All covariates associated with sum 
EETs ( P < 0.15) in a univariate analysis were carried forward into 
a stepwise multivariate analysis that included forward selection 
and backward elimination. Although hyperlipidemia status did 
not meet these criteria ( P = 0.35), this covariate was also consid-
ered in the modeling. Collinear variables (variance infl ation fac-
tor >10 or condition index >30) were removed, and covariates 
with  P < 0.15 were retained in the fi nal adjustment model. A 
model was also constructed for sum EETs + DHETs levels. 
 Metabolomic analyses [Student’s  t -tests for each individual 
metabolite followed by false discovery rate (FDR) analyses and 
quantitative enrichment analysis (QEA)] were performed with 
Metaboanalyst 3.0 ( 19 ). For these analyses, biomarker compari-
sons were conducted between those with obstructive CAD and 
all other patients (no apparent CAD and nonobstructive CAD 
groups were combined and served as a single reference group). 
Metabolites with  P < 0.05 and FDR  q < 0.05 were considered sig-
nifi cantly different across obstructive CAD status. Metabolites 
within the same pathway tended to be positively correlated with 
each other (supplementary Figure 1). In order to determine the 
most enriched eicosanoid metabolic pathways across obstructive 
CAD status, metabolites were then assigned to nine distinct eico-
sanoid metabolic pathways according to their parent substrate 
and biosynthesis enzyme. QEA was conducted to determine the 
relative impact of obstructive CAD on the nine eicosanoid meta-
bolic pathways.  P values for each pathway were generated from 
observed  Q statistics. The  Q statistic for each pathway was deter-
mined by averaging the  Q statistics for each metabolite within 
that pathway. Pathways were considered signifi cantly enriched 
when  P < 0.05 and corresponding FDR  q < 0.05. 
 The relationship between baseline CAD extent and time to oc-
currence of the primary end point (cardiovascular death, nonfa-
tal ACS event, coronary revascularization) was assessed with Cox 
proportional hazards regression. Due to a low number of events 
in those with no apparent (0 events) or nonobstructive (4 events) 
CAD, the association between baseline EET levels (tertiles) and 
the primary end point was explored exclusively within the ob-
structive CAD patients. Due to the low number of events, time-
to-event analyses were unadjusted. Kaplan-Meier curves were 
generated using GraphPad Prism 6.0. 
 RESULTS 
 Study population 
 The demographic and clinical characteristics of the 
study population are shown in  Table 1 .  Of 162 partici-
pants, 72 (44%) were diagnosed with obstructive CAD, 
51 (31%) were diagnosed with nonobstructive CAD, 
and 39 (24%) exhibited no apparent CAD. Several indi-
ces of CAD burden were signifi cantly more prevalent 
with increasing CAD extent including history of a prior 
Total RNA was isolated using the RNeasy Miniprep kit (Qiagen, 
Valencia, CA) and reverse transcribed to cDNA using the iScript 
cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA). Expres-
sion of  CYP2J2 (Hs00356035_m1) and  EPHX2 (Hs00157403_m1) 
was quantifi ed using Taqman Assays on Demand (Applied Bio-
systems, Foster City, CA) and calculated relative to  GAPDH 
(Hs02758991_g1) using the 2 -  Ct method, as previously described 
( 17 ). 
 Time-to-event analysis of cardiovascular outcomes 
 The incidence of future cardiovascular events was abstracted 
from the electronic medical record from the time of the index 
angiography through August 2014. Those who did not present to 
the UNC health care system for routine follow-up or emergent 
care after the index coronary angiography visit were considered 
to be lost to follow-up and were excluded from the analysis. The 
prespecifi ed primary end point was the time to the fi rst occur-
rence of death due to a cardiovascular cause, hospitalization for 
a nonfatal acute coronary syndrome (ACS) event (unstable an-
gina, non-STEMI, STEMI), or hospitalization for a coronary re-
vascularization procedure (PCI or CABG). Clinician-reported 
outcomes were verifi ed from the electronic medical records by 
two individuals. 
 Statistical analysis 
 Data are presented as mean ± standard deviation, median (in-
terquartile range), or count (%). All analyses were performed 
using SAS 9.3 (SAS Institute, Cary, NC), and  P < 0.05 was consid-
ered statistically signifi cant, unless otherwise indicated. Study 
population characteristics were compared across CAD extent us-
ing one-way ANOVA for continuous data and Chi-square test or 
Fisher’s exact test for categorical data as appropriate. 
 Metabolite levels and epoxide/diol ratios were not normally 
distributed and thus log-transformed prior to statistical analysis. 
Pearson correlations between individual metabolites were evalu-
ated. Signifi cant correlations were observed among the EET as 
well as the DHET regioisomers (supplementary Figure 1). Thus, 
to minimize redundancy, the sum of the 8,9-, 11,12-, and 14,15-
EET regioisomers (sum EETs) and the 5,6-, 8,9-, 11,12-, and 
14,15-DHET regioisomers (sum DHETs) were calculated ( 13 ). 
The sum EETs served as the primary end point for comparison 
across CAD extent. The sum of the EET and DHET regioisomers 
(sum EETs + DHETs) and the ratio of 14,15-EET to 14,15-DHET 
(14,15-EET:14,15-DHET ratio) (secondary end points) were cal-
culated as biomarkers of CYP epoxygenase and sEH metabolic 
function, respectively ( 18 ). 
 The sum EETs, sum EETs + DHETs, and 14,15-EET:14,15-
DHET ratio were compared across CAD extent by ANOVA (un-
adjusted). Comparisons across CAD extent were also completed 
after adjusting for demographic factors (age, African American 
race, sex) and clinical factors that were independently associated 
with CAD extent ( P < 0.15) in a multivariable model (diabetes, 
prior acute myocardial infarction, beta blocker use, angiotensin-
converting enzyme inhibitor use). Hyperlipidemia status was also 
included in the adjusted model due to the potential impact of li-
poprotein levels on free EET concentrations in plasma. Post hoc 
pairwise comparisons were conducted using Fisher’s least signifi -
cant difference (LSD) test. In order to obtain additional insight 
into these analyses, the following comparisons across CAD extent 
were explored: sum DHETs, individual EET and DHET regioiso-
mers, other biomarkers of sEH metabolic function (11,12-
EET:11,12-DHET; 8,9-EET:8,9-DHET; sum EETs:sum DHETs; 
12,13-epoxyoctadecaenoic acid to dihydroxyoctadecaenoic acid 
[EpOME:DHOME]), and PBMC expression of  CYP2J2 and  EPHX2 . 
 To determine the magnitude of the association between sum 
EETs and CAD extent relative to other demographic and clinical 
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 A similar inverse relationship was observed between 
CAD extent and free EETs+DHETs ( Fig. 1B ;  Table 2 ). In 
addition, mRNA levels of the CYP epoxygenase enzyme 
 CYP2J2 in PBMCs were inversely associated with CAD ex-
tent ( P = 0.042; supplementary Figure 2A). In contrast, the 
14,15-EET:DHET ratio was not signifi cantly associated 
with CAD extent ( Fig. 1C ;  Table 2 ). Similarly, no associa-
tion was observed between CAD extent and either the sum 
EET:DHET ratio ( Table 2 ) or the 12,13-EpOME:DHOME 
ratio biomarkers of sEH metabolic function ( P = 0.992), or 
 EPHX2 mRNA levels in PBMCs ( P = 0.320; supplementary 
Figure 2B). 
 The multivariate analysis demonstrated that CAD extent 
was a signifi cant independent predictor of EET levels 
( Table 3 ).  The presence of collaterals, compensatory anas-
tomotic bypasses between or within coronary arteries with-
out an intervening capillary bed ( 21 ), was also associated 
with lower EET levels. Moreover, use of certain medica-
tions was associated with higher (statins, calcium channel 
blockers) and lower (beta blockers, angiotensin-converting 
enzyme inhibitors) EET levels ( Table 3 ). CAD extent was 
also a signifi cant independent predictor of sum EETs + 
DHETs levels ( Table 4 ).  
 Identifi cation of altered eicosanoid pathways across 
obstructive CAD status 
 Among all of the individual eicosanoid metabolites 
quantifi ed, 11 were altered ( P < 0.05) between obstructive 
revascularization procedure ( P = 0.009) and diagnosis of 
an ACS during the index visit ( P < 0.001). The prevalence 
of CAD risk factors and medication use were comparable 
to previously reported coronary angiography cohorts and 
refl ected clinical practice guidelines ( 12, 20 ). Cholesterol 
and triglyceride levels did not signifi cantly differ across 
CAD extent. 
 Association of EET metabolic pathway biomarkers 
and CAD extent 
 The sum of free EET levels in plasma were inversely as-
sociated with CAD extent, such that EET levels in obstruc-
tive CAD patients were lower than EET levels in patients 
with either no apparent CAD or nonobstructive CAD ( Fig. 
1A ;  Table 2 ).  Sum EET levels signifi cantly differed be-
tween no apparent CAD and obstructive CAD patients 
( P < 0.05), whereas the observed difference in EET levels 
between nonobstructive CAD and obstructive CAD pa-
tients was not statistically signifi cant after adjusting for 
covariates ( P = 0.063). No difference in EET levels was ob-
served between patients with no apparent CAD and non-
obstructive CAD. Consistent results were observed with the 
individual 8,9-, 11,12-, and 14,15-EET regioisomers and 
the DHET metabolites ( Table 2 ). Furthermore, higher 
maximum coronary artery stenosis (another indicator of 
CAD extent: the percent narrowing of the most obstructed 
coronary artery) was signifi cantly associated with lower 
sum EETs (Pearson’s  r =   0.26,  P = 0.001). 
 TABLE 1. Characteristics of the total study population and across the angiographic extent of CAD 
Characteristic Total (N = 162)
No Apparent 
CAD (N = 39)
Nonobstructive 
CAD (N = 51)
Obstructive 
CAD (N = 72)  P  a 
Demographics
 Age (years) 61.8 ± 10.3 58.2 ± 10.4 62.1 ± 9.9 63.6 ± 10.2 0.028
 Female 70 (43.2%) 18 (46.2%) 22 (43.1%) 30 (41.7%) 0.901
 African American 34 (21.0%) 10 (25.6%) 11 (21.6%) 13 (18.1%) 0.640
 Body mass index (kg/m 2 ) 31.8 ± 7.5 34.0 ± 8.0 30.8 ± 8.8 31.4 ± 6.0 0.110
Past medical history
 Current/recent (<1 year) smoker 46 (28.4%) 11 (28.2%) 15 (29.4%) 20 (27.8%) 0.980
 History of hypertension 130 (80.3%) 28 (71.2%) 41 (80.4%) 61 (84.7%) 0.263
 History of diabetes 51 (31.5%) 9 (23.1%) 14 (27.5%) 28 (38.9%) 0.174
 History of hyperlipidemia 111 (68.5%) 23 (59.0%) 34 (66.7%) 54 (75.0%) 0.209
 Prior acute myocardial infarction 24 (14.8%) 1 (2.6%) 6 (11.8%) 17 (23.6%) 0.006
 Prior revascularization 56 (34.6%) 6 (15.4%) 18 (35.3%) 32 (44.4%) 0.009
Medication use
 ACE inhibitor use 73 (45.1%) 14 (35.9%) 18 (35.3%) 41 (56.9%) 0.025
 ARB use 33 (20.4%) 10 (25.6%) 13 (25.5%) 10 (13.9%) 0.187
 Aspirin use 122 (75.3%) 29 (74.4%) 37 (72.6%) 56 (77.8%) 0.793
 Beta blocker use 99 (61.1%) 16 (41.0%) 32 (62.8%) 51 (70.8%) 0.009
 Statin use 123 (75.9%) 27 (69.2%) 39 (76.5%) 57 (79.2%) 0.502
 Calcium channel blocker use 46 (28.4%) 13 (33.3%) 14 (27.5%) 19 (26.4%) 0.729
Cardiac catheterization laboratory
 ACS on presentation 29 (17.9%) 3 (7.7%) 3 (5.9%) 23 (31.9%) <0.001
 Presence of collateral 20 (12.4%) 5 (12.8%) 4 (7.8%) 11 (15.3%) <0.001
 Stenosis in most severe vessel (%) 50 (80) 0 (0) 40 (25) 90 (15) <0.001
Serum lipoprotein levels, n b 82 12 22 48
 Total cholesterol (mg/dl) 150.5 (60) 157 (53) 160.5 (60) 147 (58.5) 0.835
 LDL cholesterol (mg/dl) 82 (42) 83.5 (35.5) 83 (44) 80 (39) 0.625
 HDL cholesterol (mg/dl) 38.5 (13) 35.5 (12) 41 (11) 38.5 (14.5) 0.329
 Triglycerides (mg/dl) 140.5 (128) 164 (164.5) 162 (128) 130.5 (119.5) 0.521
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker. Data presented as mean ± standard 
deviation, median (interquartile range), or count (%).
 a One-way ANOVA across CAD extent was performed for continuous variables, and Chi-square test or Fisher’s 
exact test was performed for categorical variables.
 b A fasting lipid panel obtained for clinical purposes was available in 82 participants; comparisons of lipid levels 
were completed using log-transformed data.
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or a coronary revascularization procedure occurred in 21 
participants (0, 10, and 11 events, respectively). CAD ex-
tent at baseline was signifi cantly associated with incidence 
of a cardiovascular event, with 17 of the 21 events occur-
ring in those with obstructive CAD ( Fig. 3A ), similar to 
previous studies ( 20 ).  
 Although the presence of obstructive CAD is associated 
with lower EET levels, considerable interindividual vari-
ability in EET levels existed within the obstructive CAD 
group [median (interquartile range): 639 (286) pg/ml]. 
Consequently, we explored the relationship between base-
line EET levels and risk of a future cardiovascular event 
CAD patients (N = 72) and all other participants (N = 90) 
( Fig. 2A , B ;  Table 5 ).  The three EET and four DHET re-
gioisomers were among the 11 analytes associated with 
CAD extent. QEA revealed that only the AA-derived CYP 
epoxide and AA-derived sEH diol pathways were signifi -
cantly associated with the presence of obstructive CAD 
( Fig. 2C ;  Table 6 ).  
 Risk of future cardiovascular events 
 Follow-up data were available in 121 (75%) of the en-
rolled participants, and the median length of follow-up 
was 1.0 years. Cardiovascular death, a nonfatal ACS event, 
 Fig. 1. Plasma biomarkers of CYP-mediated EET biosynthesis and hydrolysis across CAD extent. A: Sum EETs were associated with CAD 
extent across no apparent CAD (N = 39), nonobstructive CAD (N = 51), and obstructive CAD (N = 72) patients (ANOVA: unadjusted  P = 
0.003, adjusted  P = 0.043). B: A signifi cant association was also observed with sum EETs + DHETs (ANOVA: unadjusted  P = 0.001, adjusted 
 P = 0.007). C: In contrast, the 14,15-EET:DHET ratio was not associated with CAD extent (ANOVA: unadjusted  P = 0.693, adjusted  P = 
0.747). Data presented as median (midline), interquartile range (box), and 95% confi dence intervals (whiskers). *  P < 0.05 in unadjusted 
post hoc pairwise comparisons. †  P < 0.05 in adjusted pairwise comparisons.  
 TABLE 2. Comparison of free plasma CYP epoxygenase-derived and sEH-derived AA metabolite biomarkers 
across CAD extent 
Analyte
No Apparent CAD
(N = 39)
Nonobstructive CAD
(N = 51)
Obstructive CAD
(N = 72)  P  a 
AA-CYP epoxides (pg/ml)
 14,15-EET 368 (170) 295 (170) 286 (117) d,e 0.006
 11,12-EET 192 (89) 171 (99) 152 (85) d,e 0.003
 8,9-EET 235 (125) 205 (112) 189 (87) d,e 0.007
 Sum EETs b 815 (417) 678 (356) 618 (258) d,e 0.003
AA-sEH diols (pg/ml)
 14,15-DHET 1,007 (568) 971 (449) 845 (442) d 0.006
 11,12-DHET 657 (393) 633 (367) d 563 (257) d 0.005
 8,9-DHET 300 (193) 229 (206) 217 (110) d 0.039
 5,6-DHET 290 (145) 244 (198) 229 (122) d 0.028
 Sum DHETs 2,324 (1,305) 2,084 (1,605) 1,956 (875) d 0.004
CYP epoxygenase function (pg/ml)
 Sum EETs + DHETs 3,321 (1,441) 2,737 (1,670) 2,593 (997) d,e 0.001
sEH function (ratio)
 14,15-EET:14,15-DHET 0.35 (0.18) 0.33 (0.22) 0.34 (0.16) 0.693
 11,12-EET:11,12-DHET 0.28 (0.19) 0.29 (0.19) 0.27 (0.16) 0.413
 8,9-EET:8,9-DHET 0.80 (0.44) 0.81 (0.51) 0.78 (0.31) 0.880
 Sum EETs:DHETs c 0.37 (0.22) 0.38 (0.22) 0.36 (0.18) 0.649
Data are presented as median (interquartile range).
 a One-way ANOVA was performed on log-transformed data.
 b Plasma concentrations of the 5,6-EET regioisomer were below the limit of quantifi cation and not included in 
the calculation.
 c 5,6-DHET was removed from ratio values to determine its impact on analysis because 5,6-EET could not be 
included.
 d P < 0.05 versus no apparent CAD (Fisher’s LSD). 
 e P < 0.05 versus nonobstructive CAD (Fisher’s LSD).
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anti-infl ammation by attenuating nuclear factor   B signal-
ing ( 24 ), and antiapoptosis by promoting phosphoinosit-
ide-3-kinase/Akt signaling ( 25 ). Consequently, promoting 
the effects of EETs, most notably by inhibiting sEH and 
increasing endogenous EET levels, has emerged as a car-
diovascular protective therapeutic strategy with potential 
clinical utility ( 26 ). Due in part to the technical complex-
ity of measuring EETs, which are not quantifi ed on tradi-
tional metabolomic or eicosanoid panels ( 11 ), major gaps 
in knowledge surrounding the biological and therapeutic 
importance of this pathway in human cardiovascular dis-
ease remain ( 7 ). Importantly, characterizing the relation-
ship between EET metabolite levels and CAD extent in 
humans is central to a better understanding of the func-
tional role of this pathway in the initiation and progres-
sion of CAD. Through application of a targeted LC/MS/
MS assay, the current study identifi ed a signifi cant inverse 
relationship between plasma EET levels and angiographic 
extent of CAD. Pathway analyses revealed that these differ-
ences were signifi cantly more pronounced than metabolites 
derived from CYP hydroxylase, LOX, and COX pathways. 
Taken together, these fi ndings suggest that CYP-derived 
EETs may play an important role in the pathogenesis and 
progression of CAD in humans. 
 In the current study, CAD extent was also associated 
with lower sum EETs + DHETs in plasma and  CYP2J2 ex-
pression in PBMCs, but not altered plasma EET:DHET 
ratios or  EPHX2 expression. These data suggest that the 
inverse association between EET levels and CAD extent 
was mediated by suppression of EET biosynthesis (CYP 
epoxygenase metabolism), and not an increase in EET hy-
drolysis (sEH metabolism). Accordingly, it is well estab-
lished that infl ammatory stimuli suppress CYP-mediated 
exclusively within the subset of patients with obstructive 
CAD who had follow-up data (N = 63). An inverse relation-
ship between EET levels and cardiovascular event inci-
dence appeared to exist, such that the highest number of 
events was observed in those in the lowest EET level tertile 
( Fig. 3B ); however, this relationship was not statistically 
signifi cant ( P = 0.086). 
 DISCUSSION 
 This is the fi rst study that reports a relationship between 
circulating EET metabolite levels and the angiographic ex-
tent of CAD in humans. We observed that the presence of 
obstructive CAD is signifi cantly and independently associ-
ated with lower plasma free (unesterifi ed) EET levels. Fur-
thermore, the association between obstructive CAD and 
lower EET levels  a ) correlates with lower CYP epoxygenase 
metabolic function, but not higher sEH metabolic func-
tion and  b ) is signifi cantly more pronounced than other 
eicosanoid metabolism pathways. Collectively, these fi nd-
ings suggest that the presence of obstructive CAD is as-
sociated with lower EET metabolite levels secondary to 
suppressed EET biosynthesis. Based on these fi ndings, the 
authors suggest that novel strategies that promote the ef-
fects of EETs may have therapeutic promise in patients 
with obstructive CAD. 
 It has become increasingly clear that CYPs metabolize 
AA into bioactive eicosanoids with potent cellular and 
physiological effects in the cardiovascular system ( 22 ). Most 
notably, CYP epoxygenase-derived EETs elicit protective 
effects in preclinical models ( 5, 6 ), including vasodila-
tion by hyperpolarizing vascular smooth muscle cells ( 23 ), 
 TABLE 3. Multivariate relationships between clinical factors and free plasma EETs 
Predictor a Parameter Estimate SE  P b Partial  R  2 
CAD extent   0.042 0.017 0.013 0.067
Male 0.106 0.027 <0.001 0.049
Presence of collaterals   0.099 0.041 0.017 0.032
Statin use 0.143 0.040 <0.001 0.024
Beta blocker use   0.082 0.029 0.006 0.036
History of hyperlipidemia   0.073 0.035 0.040 0.025
Calcium channel blocker use 0.057 0.030 0.060 0.017
ACE inhibitor use   0.050 0.028 0.071 0.016
Full model <0.001 0.265
 a CAD extent was coded as an ordinal variable (1 = no apparent CAD; 2 = nonobstructive CAD; 3 = obstructive 
CAD). The remaining factors were coded as nominal variables (0 = no; 1 = yes).
 b Factors with  P < 0.15 were retained in the multivariate model.
 TABLE 4. Multivariate relationships between clinical factors and free plasma sum EETs + DHETs 
Predictor a Parameter Estimate SE  P b Partial  R 2 
CAD extent   0.055 0.016 <0.001 0.080
Male 0.092 0.025 <0.001 0.060
Beta blocker use   0.071 0.028 0.012 0.022
Statin use 0.119 0.037 0.002 0.032
History of hyperlipidemia   0.056 0.034 0.098 0.014
Full model <0.001 0.208
 a CAD extent was coded as an ordinal variable (1 = no apparent CAD; 2 = nonobstructive CAD; 3 = obstructive CAD). 
The remaining factors were coded as nominal variables (0 = no; 1 = yes).
 b Factors with  P < 0.15 were retained in the multivariate model.
CYP-derived EETs and CAD in humans 115
(which did not signifi cantly differ across CAD extent) is 
predominantly derived from CYP4A11 and CYP4F2 in hu-
mans ( 31 ), suggesting that suppression of CYP-mediated 
eicosanoid biosynthesis may be isoform specifi c. 
 Altogether, these preclinical and clinical fi ndings sug-
gest that suppression of CYP epoxygenase expression and 
EET biosynthesis may be, at least in part, a key pathological 
consequence of the infl ammation-mediated development 
and progression of CAD. Although the aforementioned 
cellular and physiological effects have been attributed to 
free EETs, and sEH rapidly hydrolyzes free EETs to their 
corresponding DHET metabolites, it is well-established 
that cellular EETs are readily esterifi ed to membrane 
phospholipids ( 6, 34 ). Furthermore, >90% of plasma EETs 
are esterifi ed to lipoprotein phospholipids in rats and hu-
mans ( 35–37 ). The direct functional role of cellular and 
circulating esterifi ed EETs, however, remains unclear and 
requires further investigation ( 34, 35 ). It is important to 
note that free plasma oxylipins were quantifi ed in the cur-
rent investigation, and that changes in circulating lipopro-
tein levels have been reported to impact the relative extent 
of oxylipin esterifi cation into lipoprotein phospholipids 
( 36, 37 ). Consequently, the presence of hyperlipidemia 
and higher lipoprotein levels could have enhanced EET 
xenobiotic metabolism through a variety of mechanisms, 
including cytokine-mediated transcriptional downregula-
tion of CYP expression ( 27 ); fi ttingly, infl ammatory stim-
uli also drive the development and progression of CAD 
( 28 ). Multiple preclinical studies have also demonstrated 
that CYP epoxygenase expression and EET biosynthesis 
are suppressed in the presence of pathological infl amma-
tion. Notably, hepatic CYP epoxygenase expression, he-
patic CYP epoxygenase metabolic function, and plasma 
EET levels were suppressed in an atherogenic diet mouse 
model of infl ammatory fatty liver disease ( 29 ). In contrast, 
no changes in sEH expression or EET hydrolysis were 
observed. Although most studies have investigated the 
impact of infl ammation on hepatic CYP expression and 
function, cytokines have also been reported to downreg-
ulate CYP epoxygenase expression in endothelial cells 
( 30 ). Moreover, hepatic, renal, pulmonary, and myocardial 
Cyp2c/2j expression and EET biosynthesis were suppressed 
in an endotoxin mouse model of acute infl ammation ( 17 ). 
Interestingly, 19-HETE was among the metabolites that 
differed across obstructive CAD status. This metabolite is 
primarily biosynthesized by CYP2E1, and to a lesser extent 
CYP4A11 ( 31 ). 19-HETE is also derived from isoforms 
within the CYP2J subfamily ( 32, 33 ). In contrast, 20-HETE 
 Fig. 2. Enrichment of eicosanoid pathways across obstructive CAD status. Twenty-eight eicosanoid metabolites were assigned to 9 distinct 
eicosanoid metabolic pathways according to their parent substrate [AA, linoleic acid (LA), and EPA/DHA fatty acids] and biosynthesis 
enzyme (CYP, LOX, COX, and sEH), and compared between obstructive CAD patients (N = 72) and all other patients (N = 90). The EPA- 
and DHA-derived metabolites (all derived from CYP or sEH biosynthesis) were combined into one pathway due to the low number of me-
tabolites in that group. A: A volcano plot shows how each of the 28 individual metabolites within pathways differs between obstructive CAD 
patients and all other patients. Metabolites in the upper left box [fold change (FC) >1.2 and  P < 0.05] were considered to be signifi cantly 
altered.  P value decreases as y-axis value increases. B: A list (rank ordered by  P value with accompanying FDR and FC) of the top metabolites 
that signifi cantly differed by obstructive CAD status is provided. C: QEA revealed that AA-derived epoxides ( P = 0.001; FDR  q  = 0.010) and 
AA-derived diols ( P = 0.006; FDR  q = 0.028) were enriched across obstructive CAD status relative to parallel pathways. *QEA  P < 0.05 and 
FDR  q < 0.05. 
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of free EET concentrations, as opposed to both free and 
total concentrations, is a limitation of the current study 
because we cannot conclusively determine whether increased 
EET esterifi cation to lipoprotein phospholipids contrib-
uted, at least in part, to the observed results. Indeed, an 
improved understanding of the biological and therapeutic 
relevance of EET incorporation into phospholipids is of 
considerable interest to the fi eld ( 35 ). Future studies that 
quantify free and total EET levels are needed to further 
elucidate the mechanisms underlying the relationship be-
tween advanced CAD and lower EET levels in humans. 
esterifi cation to lipoprotein phospholipids and thus con-
tributed to the observed decrease in free EET levels in 
patients with obstructive CAD. Importantly, circulating li-
poprotein levels did not signifi cantly differ across CAD ex-
tent. Furthermore, the observed differences in free EET 
and EET + DHET levels across CAD extent persisted after 
adjusting the analysis for hyperlipidemia status. Taken to-
gether, these data suggest that differences in lipoprotein 
levels and hyperlipidemia status did not markedly impact 
the association between obstructive CAD and lower free 
plasma EET and EET + DHET levels. However, quantifi cation 
 TABLE 5. Comparison of free plasma eicosanoid metabolites by obstructive CAD status 
Analyte (pg/ml) No Obstructive CAD (n = 90) Obstructive CAD (n = 72)  P  a FDR  q 
AA-CYP epoxides
 14,15-EET 312 (164) 286 (117) 0.002 0.021
 11,12-EET 181 (99) 152 (85) <0.001 0.019
 8,9-EET 211 (100) 189 (87) 0.002 0.021
AA-sEH diols
 14,15-DHET 981 (490) 845 (442) 0.006 0.031
 11,12-DHET 642 (367) 563 (257) 0.009 0.034
 8,9-DHET 252 (194) 217 (110) 0.019 0.059
 5,6-DHET 268 (177) 229 (122) 0.008 0.034
AA-CYP hydroxyls
 19-HETE 694 (408) 588 (267) 0.006 0.031
 20-HETE 1,270 (827) 1,087 (664) 0.076 0.134
AA-LOX metabolites
 15-HETE 1,021 (620) 847 (382) 0.010 0.036
 11-HETE 6,361 (3,944) 5,361 (3,222) 0.024 0.066
 12-HETE 70 (42) 53 (38) 0.047 0.101
 8-HETE 13,028 (8,100) 12,094 (5,639) 0.068 0.134
 5-HETE 2,426 (1,707) 2,068 (1,478) 0.076 0.134
LA-CYP epoxides
 12,13-EpOME 1,786 (918) 1,652 (1,127) 0.083 0.135
 9,10-EpOME 4,350 (2,562) 3,817 (2,921) 0.046 0.101
LA-sEH diols
 12,13-DHOME 2,911 (1,916) 2,466 (1,929) 0.109 0.170
 9,10-DHOME 1,961 (1,162) 1,432 (1,158) 0.046 0.101
LA-LOX metabolites
 13-HODE 21,839 (10,222) 19,661 (12,561) 0.141 0.208
 9-HODE 15,489 (8,711) 14,728 (10,611) 0.180 0.230
 9,12,13-TriHOME 718 (742) 668 (829) 0.240 0.292
 9,10,13-TriHOME 9,478 (742) 8,406 (13,552) 0.304 0.340
EPA/DHA-epoxides/diols
 19,20-EpDPE 1,666 (1,477) 1,641 (888) 0.253 0.295
 19,20-DiHDPA 1,206 (741) 1,188 (596) 0.581 0.603
 17,18-DHET 2,806 (2,184) 2,671 (1,740) 0.181 0.230
AA-COX metabolites
 8-iso-PGF2  29 (11) 28 (12) 0.157 0.220
 6-keto-PGF1  51 (20) 50 (21) 0.748 0.748
 PGF2  229 (539) 326 (788) 0.379 0.409
DiHDPA,dihydroxydocosapentaenoic acid; EpDPE, epoxydocosapentaenoic acid; PGF, prostaglandin F; 
TriHOME, trihydroxyoctadecenoic acid. Data presented as median (interquartile range ).
 a Student’s  t -test was performed on log-transformed data followed by FDR calculations to account for multiple testing.
 TABLE 6. QEA results on eicosanoid metabolic pathways 
Metabolites (N) Observed  Q Expected  Q  P  a FDR  q 
 AA-CYP epoxides  3  6.14  0.62  0.001  0.010 
 AA-sEH diols  4  3.82  0.62  0.006  0.028 
AA-CYP hydroxyls 2 2.87 0.62 0.023 0.070
AA-LOX metabolites 5 2.45 0.62 0.041 0.090
LA-CYP epoxides 2 2.17 0.62 0.058 0.090
LA-sEH diols 2 2.14 0.62 0.060 0.090
LA-LOX metabolites 4 0.91 0.62 0.221 0.284
EPA/DHA-epoxides/diols 3 0.70 0.62 0.303 0.341
AA-COX metabolites 3 0.51 0.62 0.374 0.374
 a QEA was performed on log-transformed data, and  P values were generated from observed  Q statistics. Bold 
indicates QEA  P < 0.05 and FDR  q < 0.05.
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Moreover, in the present study, statin use was positively 
associated with sum EET levels in the multivariable analy-
sis. Furthermore, participants in the present study were 
recruited from a single population and the reference 
subpopulation with no apparent angiographic evidence of 
CAD had similar CAD risk factors, circulating lipoprotein 
levels, and medication use compared with those with non-
obstructive and obstructive CAD. Thus, there was reduced 
potential for confounding factors between these clinically 
relevant stages of CAD. Moreover, the observed associa-
tion between EET levels and CAD extent was indepen-
dent of clinical factors and medication use in an adjusted 
model. Future prospective studies are needed to delin-
eate the direct effects of medication use such as statins 
and comorbid conditions such as hyperlipidemia on EET 
biosynthesis and hydrolysis in patients at risk for or with 
CAD. 
 The relationship between metabolite biomarkers of the 
EET metabolic pathway and prognosis in patients with es-
tablished CAD has not been studied to date. Therefore, we 
explored the relationship between baseline EET levels and 
risk of a future adverse cardiovascular event in patients 
with obstructive CAD at baseline. We observed an inverse 
relationship across the EET tertiles where the highest 
event incidence occurred in those with the lowest EET lev-
els at baseline. This relationship was not statistically signifi -
cant and should be interpreted with caution due to the 
small number of events. These fi ndings, however, are bio-
logically plausible considering the anti-infl ammatory and 
protective effects of EETs in numerous preclinical models 
of cardiovascular disease. Furthermore, these data are 
consistent with a previously reported inverse association 
between circulating EET and monocyte chemoattractant 
 A few additional studies have quantifi ed plasma EET lev-
els in patients at risk for or with established cardiovascular 
disease. Ramirez et al. ( 38 ) found that presence of the 
metabolic syndrome was associated with lower circulating 
EET levels. Furthermore, Minuz et al. ( 39 ) reported that 
patients with renovascular disease had lower circulating 
EETs compared with both healthy volunteer and essential 
hypertension controls. In contrast, we previously reported 
that a cohort of patients with established CAD (defi ned as 
history of coronary artery stenosis   50% or a revascular-
ization procedure) had higher plasma EET levels com-
pared with a population of healthy volunteer controls 
( 40 ). Higher EET levels appeared to be driven by sup-
pressed sEH metabolic function, such that the median 
14,15-EET:DHET ratio was signifi cantly higher in CAD 
cases compared with healthy volunteers (0.37 vs. 0.18, re-
spectively). In the present study, however, no differences 
in sEH metabolic function, or  EPHX2 mRNA levels in 
PBMCs, were observed across those with no apparent 
(0.35), nonobstructive (0.33), and obstructive CAD (0.34). 
Direct comparison of the prior and present study should 
be completed with caution because the controls in the 
prior study were healthy volunteers that had no CAD risk 
factors and were not receiving medication for any chronic 
conditions. Consequently, multiple potential confound-
ing factors may have driven the apparent suppression of 
sEH metabolic function in CAD cases. Statins, for exam-
ple, were taken by 93% of CAD cases and none of the con-
trols ( 40 ), and may have directly increased EET levels. 
Statins have been reported to increase 14,15-EET levels in 
human neutrophils and bronchial epithelial cells, poten-
tially due to suppression of sEH activity ( 41 ), and increase 
CYP epoxygenase expression in endothelial cells ( 42 ). 
 Fig. 3.  CAD extent, EETs, and risk of subsequent cardiovascular events. Kaplan-Meier curves were generated for incidence of the primary 
end point (time to the occurrence of death from cardiovascular causes, ACS event, or coronary revascularization procedure) according to 
CAD extent at baseline in all patients with reliable follow-up data (N = 121) (A) and free plasma EET levels at baseline (tertiles) exclusively 
within the subset of patients with obstructive CAD (N = 63) (B). The log rank  P value (unadjusted) for each Kaplan-Meier curve is provided. 
Below the curves, the number and frequency of events within each CAD extent and EET tertile group, along with the unadjusted hazard 
ratio (HR), 95% confi dence interval (CI), and  P value, are provided. Due to the lack of events in those with no apparent CAD at baseline, 
the no apparent CAD and nonobstructive CAD groups were combined and served as a single reference group. 
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quantifi cation of CYP-derived eicosanoids in the clinical 
setting is advancing ( 50 ). Consequently, our results set 
the foundation for future clinical research in this area, 
including the rational design of prospective, biomarker-
guided interventional studies in targeted subsets of the 
CAD population (low EET levels) with enriched potential 
to derive clinical benefi t from emerging EET-promoting 
therapies.  
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protein 1 (MCP-1) concentrations [a proinfl ammatory 
chemokine predictive of poor prognosis in CAD ( 43 )], in 
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EET tertiles had signifi cantly higher MCP-1 levels com-
pared with those in the highest EET tertile ( 18 ). These 
preliminary observations underscore the need to rigor-
ously evaluate the relationship between EET levels and the 
risk of cardiovascular events in larger populations. 
 Although the current study is the largest to date evaluat-
ing the relationship between CYP-derived eicosanoid me-
tabolites and CAD in humans, our analysis has limitations 
that must be acknowledged. Due to the cross-sectional de-
sign of the present study, causality between plasma EET 
levels and CAD extent cannot be established. Consequently, 
we are unable to discern whether low EET levels result 
from the presence of obstructive CAD or whether low EET 
levels are a causal factor in the development of obstructive 
CAD. Additionally, metabolomic analyses of a panel of 28 
metabolites included multiple statistical comparisons. To 
account for the possibility of false-positive fi ndings, an 
FDR was calculated for each comparison. Associations 
were deemed signifi cant if FDR  q < 0.05, which enhanced 
confi dence in our results. Validation of the observed rela-
tionships in an independent cohort will ultimately be neces-
sary. Finally, numerous potentially important eicosanoids 
were either below the limit of quantitation or not evaluated 
by the used LC/MS/MS method. In particular, COX-derived 
prostaglandins are naturally found in low abundance in 
human plasma, and their quantifi cation in peripheral 
blood is complicated by rapid metabolism and artifactual 
ex vivo formation ( 44 ). Alternative strategies, such as 
quantifi cation in peripheral blood following ex vivo stimu-
lation or in urine, were beyond the scope of the current 
investigation. Thus, future studies that integrate multiple 
analytical platforms and sampling strategies will be needed 
to more precisely discern the association between EETs and 
CAD extent relative to prostaglandins and a broader array 
of bioactive lipids. 
 Recent failures in CAD drug development suggest that 
innovative approaches are needed to mitigate increasing 
attrition rates and more successfully translate novel therapies 
into clinical practice ( 45 ). Compared with the conven-
tional “one size fi ts all” methodology to drug develop-
ment, a precision medicine approach has the potential to 
increase the probability of success for promising therapeu-
tic candidates ( 46 ). Although targeted therapies are rou-
tinely used in oncology, this strategy has not been readily 
adopted in CAD. Biomarkers offer considerable promise 
to prospectively identify subsets of CAD patients at high 
risk of experiencing a cardiovascular event that exhibit 
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thereby enabling novel therapies that target the pathway 
to maximize their therapeutic effect and improve out-
comes. Our fi ndings offer important insight into the po-
tential therapeutic utility of increasing EETs in obstructive 
CAD patients predisposed to low EET levels. Importantly, 
agents that promote the effects of EETs are in early 
development for a variety of therapeutic indications ( 47–
49 ). In parallel, technology for the high-throughput 
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